Navigation Links
NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
Date:7/22/2008

SOPHIA ANTIPOLIS, France, July 22 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced it has successfully completed the enrollment of 417 osteoarthritis (OA) patients with controlled hypertension in two clinical pharmacology studies in the United States, in line with previously announced timelines. These trials are designed to assess the blood pressure profile of naproxcinod, in comparison to ibuprofen and naproxen, using the Ambulatory Blood Pressure Monitoring (ABPM) technique. Results of both studies are expected in Q4 2008. Naproxcinod is NicOx' lead investigational drug and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is currently in phase 3 clinical development for the treatment of the signs and symptoms of OA, with results of the last two phase 3 studies anticipated in the second half of 2008.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen and naproxen, are commonly used by OA patients to control their chronic pain, inflammation and stiffness. However, these important products have the tendency to raise blood pressure, a side effect of particular concern in OA patients due to the high prevalence of hypertension and other cardiovascular risk factors in this elderly population.

The objectives of these phase 1 ABPM trials, known as the 111 and 112 studies, are to provide important additional data on the 24-hour blood pressure profile of naproxcinod in chronically treated OA patients with controlled hypertension, in comparison to commonly used NSAIDs. The 111 is a 12-week study, which has enrolled 118 patients at 30 clinical sites, who are receiving increasing doses of either naproxcinod or naproxen at three week intervals. The 112 study has enrolled 299 patients at 60 clinical sites, which have been randomized to five groups, receiving 13 weeks of treatment with: naproxcinod 375 mg bid (twice daily), naproxcinod 750 mg bid,
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
5. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
6. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
7. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
8. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
11. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... SHANGHAI , Sept. 22, 2014 /PRNewswire/ ... knowledge leader in healthcare technology, media and telecommunications, ... innovation in China and ... Continua and BHG announced this new partnership during ... week in Washington, DC , ...
(Date:9/22/2014)... Sept. 22, 2014 Research and ... "Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, ... report to their offering. On ... ablation technologies market has been divided into eight ... cryotherapy, hydrothermal, and hydromechanical ablation technologies. The light/laser ...
(Date:9/22/2014)... , Sept. 22, 2014  Olympus, a global ... for medical and surgical procedures, among other core ... with Munich -based Brainlab to ... Navigation. This agreement applies to the US ... U.S. sales and all distribution outside the U.S. ...
Breaking Medicine Technology:Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 2Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 3Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 4Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 2Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4
... As global food insecurity reaches all-time highs, Elanco seeks ... impact this growing crisis. Today, the company announced its ... a partnership with Heifer International. Elanco, ... global pharmaceutical corporation, is also dedicated to helping create ...
... IDEV Technologies, Inc. (IDEV) today announced the completion of ... evaluating the use of IDEV,s SUPERA® stent system for ... artery (SFA).  Enrollment was completed in May, making SUPERB ... The trial is a prospective, single-arm study of 258 ...
Cached Medicine Technology:Elanco Announces Commitment to Fight World Hunger 2Elanco Announces Commitment to Fight World Hunger 3IDEV Technologies Announces Completion of SUPERB Clinical Trial Enrollment 2
(Date:9/22/2014)... 22, 2014 Quincy Bioscience, one ... States, promotes National Self-Improvement Month this ... individuals should have access to self-improvement resources, especially ... The demand for products that preserve health is ... before. For over six years, Quincy Bioscience has ...
(Date:9/22/2014)... Orange, NJ. September 22, 2014. Kessler researchers have ... a 10-week psychoeducational wellness program in people with ... mood, overall mental health, perceived stress, and pain. ... group for individuals living with MS: Description and ... 3 in the International Journal of MS ...
(Date:9/22/2014)... UK (PRWEB) September 22, 2014 The ... in the recent years. The statistically important data received ... safety of cancer vaccines. The primary challenge to the ... information about the exact mechanism of how a human’s ... to various results in different individuals owing to known ...
(Date:9/22/2014)... The Workgroup for Electronic Data ... on the use of health IT to create ... its recent industry survey on the use of ... transactions adopted under the Health Insurance Portability and ... August 20 to September 5, which included 262 ...
(Date:9/22/2014)... 22, 2014 As concerns about ... power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) in gynecological surgeries ... detailing the continued use of uterine morcellation by ... specifically discouraged these procedures. According to The Wall ... cancer risks associated with power morcellators are overblown, ...
Breaking Medicine News(10 mins):Health News:Quincy Bioscience Promotes National Self-Improvement Month 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4
... PHILADELPHIA, Pennsylvania, June 4 ... Updates Findings Related to Australian Sponsored,Publication Practices From ... leading international publisher of scientific, technical and,medical (STM) ... moved,to provide consistent internal guidelines for its pharmaceutical ...
... , FRANKLIN, Mass., June 4 PLC Systems Inc. (OTC ... vascular medical device-based technologies, today announced the appointment of Louis ... Brenner, currently Senior Vice President at AMAG Pharmaceuticals, Inc., fills ... seek re-election. , , Dr. Brenner, 39, brings to ...
... research that has suggested excess weight worsens disease , THURSDAY, ... may not worsen asthma, as many experts have thought, but ... manage the chronic condition. , Inhaled corticosteroids are the most ... with asthma, many of whom are overweight or obese. , ...
... June 4 Last night, the America,s Health Insurance ... Keystone Mercy Health Plan, Group Health Cooperative of South ... plans with innovative programs designed to improve the health ... on a tradition among health plans of working with ...
... Research Hospital(R) celebrated its 7th annual FedEx/St. Jude Angels & ... on May 16th, at the InterContinental Hotel in Miami, Florida. ... El Gordo y La Flaca presented Tommy and ... to children,s causes and for their contributions to the entertainment ...
... Finding could help those with potentially deadly conditions , ... your blood miraculously stops flowing and forms a scab ... down to the molecular level. , "The human body ... and bruises," study co-author Wesley P. Wong, a principal ...
Cached Medicine News:Health News:Elsevier to Create New Guidelines for Pharmaceutical Article Reprint, Compilation and Custom Publications 2Health News:Elsevier to Create New Guidelines for Pharmaceutical Article Reprint, Compilation and Custom Publications 3Health News:PLC Systems Announces Appointment of Louis Brenner, M.D. to Board of Directors 2Health News:Obesity May Dampen Response to Asthma Meds 2Health News:AHIP Foundation Announces 2009 Community Leadership Awards 2Health News:Photos: Tommy & Thalia Mottola Honored at 7th Annual FedEx/St. Jude Angels & Stars Gala 2Health News:Photos: Tommy & Thalia Mottola Honored at 7th Annual FedEx/St. Jude Angels & Stars Gala 3Health News:Researchers Detect Blood-Clotting Mechanism 2
... PW 41 is a powerful, compact ... washers/aspirators, with built-in vacuum and dispensing ... ,are user-adjustable, with vertical and horizontal ... level detectors on wash and waste ...
... LHW is a solid made, manual ... Separate valves for dispense and aspirate ... comes complete with a stand and ... can be used, as well as ...
... ELx50 is a fast and versatile automated strip ... manifold. It is a self contained and programmable ... fluidic delivery from the gentle dripping of a ... pressure delivery systems. ELx50/12V processes 1 x 12 ...
... throughput washer for high ... throughput system washer is ... powerful dispensing line and ... stronger, external vacuum source. ...
Medicine Products: